NCT06314529Recruiting
Long-term Follow-up Study of BHC001 for TDT
Long-term Follow-up Study of BHC001 in the Treatment of Transfusion-dependent β-thalassemia
Source: ClinicalTrials.gov · Last updated 18 Mar 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 6 (estimated)
- First submitted
- 6 Mar 2024
- Start date
- Dec 2022
- Primary completion date
- Dec 2036
- Lead sponsor
- Bioray Laboratories
- Diseases
- Thalassaemia
- NCT number
- NCT06314529
What you commit to
- Study type: Observational
- Planned participants: 6
- From Dec 2022 to the primary completion date, Dec 2036
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- There are no exclusion criteria for this study
Who the study is looking for
- Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
- Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Age in the registry: 5 years to 35 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xiangya Hospital of Central South University Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
| The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army Coordinator of this site? Confirm its status | Nanning | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.